SLC2A6

Across TCGA pan-cancer cohorts, SLC2A6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC2A6 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SLC2A6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC2A6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, LUAD, and STAD are the cancer types where SLC2A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	DFS	Median	All	0.123	0.871	<.001	12	view →
LUAD	DFS	Median	All	0.036	0.768	<.001	12	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
SKCM	OS	Median	III,IV	0.232	0.708	.001	12	view →
LIHC	OS	Median	II,III,IV	0.178	0.695	.010	9	view →
UCEC	DFS	Median	All	0.959	0.634	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC2A6–THYM (DFS)

Open the THYM breakdown →